Hyperpolarized 129Xe MRI for imaging NK cell therapy of lung metastasis
超极化 129Xe MRI 用于肺转移的 NK 细胞治疗成像
基本信息
- 批准号:10646013
- 负责人:
- 金额:$ 18.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-05-01 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdoptive TransferAffectAllogenicAnatomyAnimalsAntigensBiodistributionBiopsyCell Culture TechniquesCell TherapyCellsCellular immunotherapyChemicalsChildChildhood Cancer TreatmentClinicClinicalDevelopmentErythrocytesExcisionFDA approvedFluorocarbonsFoundationsGasesGoalsImageImaging DeviceImmuneImmunotherapyInfusion proceduresInhalationKineticsLabelLogisticsLungMagnetic Resonance ImagingMalignant NeoplasmsMetastatic Neoplasm to the LungMethodsModalityModelingMonitorNK cell therapyNatural Killer Cell ImmunotherapyNatural Killer CellsNeoplasm MetastasisPatientsPhase I Clinical TrialsPhysiologyPlasmaPositron-Emission TomographyProtocols documentationRadiationRadiation Dose UnitRecurrenceRefractoryReportingResolutionRespiratory physiologySafetySensitivity and SpecificitySolid NeoplasmStructure of parenchyma of lungT-LymphocyteTechnologyTherapeuticTimeTissuesTracerTreatment FailureValidationVisualizationWaterabsorptionamphiphilicityanatomic imagingbiomedical imagingcancer therapycellular imagingclinical translationcostcytotoxicitydensitydetection sensitivityelectronic cigarette usefeasibility testingimaging approachimaging biomarkerimaging modalityimmune imagingimprovedin vivoinnovationinsightinterestiron oxide nanoparticlelung imagingmetabolic imagingmigrationmortalitynanoDropletnon-invasive imagingnovel strategiesnuclear imagingosteosarcomapediatric patientsrespiratory gasrespiratory imagingresponseserial imagingsoft tissuesuccesssuperparamagnetismtranslatable strategytumorvolunteer
项目摘要
Abstract. Emerging cell-based therapies may greatly improve therapeutic success of cancer treatment. NK cell
immunotherapy is particularly important in treatment of pediatric cancers, where information on tumor
immunogens is lacking. Recently, there has been increased interest in the use of adoptive transfer of ex-vivo
expanded NK cells for the treatment of solid tumors due to their innate features, higher safety compared to T
cells and lower cost. This emerging therapy is of particular importance in osteosarcoma where 30-35% of patients
die of pulmonary metastases due to a treatment-failure rate of 85% in this patient group. However, an important
problem with implementation of cell therapies in the clinic is our inability to readily assess the presence and
distribution of therapeutic cells after administration. Visualization of immune cell distribution and migration with
non-invasive imaging could offer significant new insight into the progression of immunotherapy between infusion
and invasive biopsy or resection. Although there are a number of viable approaches for imaging of
immunotherapy, all current strategies have limitations and no technology has been proven as a single solution
for longitudinal imaging of cellular immunotherapies. Therefore, it is important to continue pushing the limits of
available imaging tools in order to find solutions that would address the pressing clinical needs. Hyperpolarized
(HP) 129Xe MRI has recently emerged as a promising modality for direct imaging of respiratory function and gas
absorption. Spectral separation between HP 129Xe gas in the airspace, tissue/plasma, and red blood cells permits
quantification of gas absorption and exchange. Further, a few exploratory studies have demonstrated that
chemical exchange saturation transfer (CEST) of HP 129Xe in perfluorocarbon nanodroplets (PFC NDs) can
significantly enhance sensitivity to the presence of PFC ND’s due to a strong chemical shift between 129Xe gas
in PFC and water. We see these developments as a tremendous opportunity to develop clinically translatable
strategy for imaging NK cell therapy in the lungs. Here we propose to develop foundation for HP 129Xe CEST
(hyperCEST) MRI of NK cells in vivo. The secondary goal is identification of imaging biomarkers of functional
HP 129Xe MRI that may provide additional insight into response to cell immunotherapy. We will rely on our
extensive expertise in (i) synthesis and applications of PFC NDs in biomedical imaging including cell labeling,
and (ii) quantitative MRI, multinuclear imaging (13C, 19F, 129Xe) and metabolic imaging. Our hypothesis is that
labeling of NK cells with PFC NDs optimized for 129Xe hyperCEST MRI will not adversely affect their functionality
and will allow non-invasive NK cell monitoring with high sensitivity and specificity in the lungs. At the completion
of these studies we will have a combination of optimized and validated probes for NK cell 129Xe hyperCEST MRI
with corresponding imaging protocols that will provide foundation for further development of this promising
technology towards clinical translation.
抽象的。新兴的基于细胞的疗法可能会极大地提高癌症治疗的成功率。NK细胞
免疫疗法在儿童癌症的治疗中尤为重要,在儿童癌症治疗中,有关肿瘤的信息
缺乏免疫原。近年来,体外领养转移的应用越来越受到人们的关注。
扩增的NK细胞因其固有的特性用于实体瘤的治疗,与T细胞相比安全性更高
电池和更低的成本。这种新出现的疗法对骨肉瘤尤其重要,在骨肉瘤中,30%-35%的患者
在这组患者中,治疗失败率为85%,死于肺转移。然而,一个重要的问题是
在临床上实施细胞疗法的问题是我们不能容易地评估存在和
给药后治疗细胞的分布情况。免疫细胞分布和迁移的可视化
非侵入性成像可以为免疫治疗的进展提供重要的新视角
和侵入性活组织检查或切除。虽然有许多可行的方法来成像
免疫疗法,所有目前的策略都有局限性,没有一种技术被证明是单一的解决方案
用于细胞免疫疗法的纵向成像。因此,继续挑战极限很重要
现有的成像工具,以便找到能够满足紧迫临床需求的解决方案。超极化
(惠普)129Xe磁共振成像最近已经成为一种很有前途的呼吸功能和气体直接成像方法
吸收。空气中HP 129Xe气体、组织/血浆和红细胞之间的光谱分离
气体吸收和交换的量化。此外,一些探索性研究已经证明
HP 129Xe在全氟碳纳米液滴中的化学交换饱和转移(CEST)
由于129Xe气体之间的强烈化学位移,显著提高了对PFC-ND存在的敏感性
在PFC和水中。我们认为这些进展是开发临床可翻译的巨大机会。
肺部NK细胞治疗的成像策略。在这里,我们建议为HP 129Xe CEST开发基础
活体NK细胞的高CEST磁共振成像。第二个目标是鉴定功能性的成像生物标记物。
HP 129Xe MRI,可为细胞免疫治疗的反应提供额外的洞察力。我们将依靠我们的
在(I)PFC NDS的合成和在生物医学成像中的应用包括细胞标记方面的广泛专业知识,
(Ii)定量MRI、多核成像(13C、19F、129Xe)和代谢成像。我们的假设是
用针对129Xe HyperCEST MRI优化的PFC NDS标记NK细胞不会对其功能产生不利影响
并将允许在肺部进行具有高灵敏度和特异度的非侵入性NK细胞监测。在完成时
在这些研究中,我们将有针对NK细胞129Xe HyperCEST MRI的优化和验证探针的组合
以及相应的成像协议,将为进一步开发这一有前景的
面向临床翻译的技术。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
James A Bankson其他文献
James A Bankson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('James A Bankson', 18)}}的其他基金
HDO Imaging is a Quantitative Marker of Cerebral Glucose Oxidation
HDO 成像是脑葡萄糖氧化的定量标志物
- 批准号:
10687186 - 财政年份:2022
- 资助金额:
$ 18.93万 - 项目类别:
Leveraging Hyperpolarized MRI for Precision Oncology Approaches in Head and Neck Cancer
利用超极化 MRI 实现头颈癌的精准肿瘤学方法
- 批准号:
10530043 - 财政年份:2022
- 资助金额:
$ 18.93万 - 项目类别:
Multi-Site Development & Evaluation of a Quantitative 3D Hyperpolarized C-13 MRI Clinical Prostate Cancer Exam
多站点开发
- 批准号:
10115625 - 财政年份:2017
- 资助金额:
$ 18.93万 - 项目类别:
Array Detectors for Accelerated Small Animal MRI
用于加速小动物 MRI 的阵列探测器
- 批准号:
6830546 - 财政年份:2004
- 资助金额:
$ 18.93万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 18.93万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 18.93万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 18.93万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 18.93万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 18.93万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 18.93万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 18.93万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 18.93万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 18.93万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 18.93万 - 项目类别: